Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Athena Diagnostics | RCV000518049 | SCV000615790 | benign | not specified | 2023-10-11 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000901830 | SCV001046219 | likely benign | not provided | 2024-01-08 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003243165 | SCV003943598 | uncertain significance | Inborn genetic diseases | 2023-04-07 | criteria provided, single submitter | clinical testing | The c.1705T>A (p.Y569N) alteration is located in exon 11 (coding exon 11) of the TGM6 gene. This alteration results from a T to A substitution at nucleotide position 1705, causing the tyrosine (Y) at amino acid position 569 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |